< 生产厂家价格 >

地屈孕酮

地屈孕酮用途

Dydrogesterone(Duphaston)是口服活性的孕激素,可作用于孕酮缺乏相关疾病。

点击显示

地屈孕酮名称

[ CAS 号 ]:
152-62-5

[ 中文名 ]:
去氢孕酮

[ 英文名 ]:
Dydrogesterone

[中文别名 ]:

[英文别名 ]:

Dydrogesterone
D6-Retroprogesterone
δ6-Retroprogesterone
9β,10α-Pregna-4,6-diene-3,20-dione (8CI)
9b,10a-Pregna-4,6-diene-3,20-dione
(9β,10α)-Pregna-4,6-diene-3,20-dione
EINECS 205-806-8
6-Dehydro-9b,10a-progesterone
MFCD00867864
10a-Isopregnenone

地屈孕酮生物活性

[ 描述 ]:

Dydrogesterone(Duphaston)是口服活性的孕激素,可作用于孕酮缺乏相关疾病。

[ 相关类别 ]:

信号通路 >> 其他 >> 孕激素受体

研究领域 >> 内分泌

[参考文献]

[1]. Dydrogesterone, From Wikipedia, the free encyclopedia

[相关活性小分子]

地屈孕酮物理化学性质

[ 密度 ]:
1.1±0.1 g/cm3

[ 沸点 ]:
462.8±45.0 °C at 760 mmHg

[ 熔点 ]:
168-173°C

[ 分子式 ]:
C₂₁H₂₈O₂

[ 分子量 ]:
312.446

[ 闪点 ]:
172.2±25.7 °C

[ 精确质量 ]:
312.208923

[ PSA ]:
34.14000

[ LogP ]:
3.58

[ 蒸汽压 ]:
0.0±1.1 mmHg at 25°C

[ 折射率 ]:
1.557

[ 储存条件 ]:
Refrigerator

地屈孕酮毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: TU3671000

CHEMICAL NAME :: 9-beta,10-alpha-Pregna-4,6-diene-3,20-dione

CAS REGISTRY NUMBER :: 152-62-5

LAST UPDATED :: 199504

DATA ITEMS CITED :: 9

MOLECULAR FORMULA :: C21-H28-O2

MOLECULAR WEIGHT :: 312.49

WISWESSER LINE NOTATION :: L E5 B666 OV KU MUTJ A1 E1 FV1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >4600 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,324,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >7200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,324,1982 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 70 mg/kg

SEX/DURATION :: female 14 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Fertility - other measures of fertility

REFERENCE :: CCPTAY Contraception. (Geron-X, Inc., POB 1108, Los Altos, CA 94022) V.1- 1970- Volume(issue)/page/year: 5,57,1972

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1600 mg/kg

SEX/DURATION :: female 13-28 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - urogenital system

REFERENCE :: ACENA7 Acta Endocrinologica (Copenhagen). (Periodica, Skolegade 12 E, DK-2500 Valby, Denmark) V.1- 1948- Volume(issue)/page/year: 43,539,1963

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 40 mg/kg

SEX/DURATION :: female 13-28 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - urogenital system

REFERENCE :: ACENA7 Acta Endocrinologica (Copenhagen). (Periodica, Skolegade 12 E, DK-2500 Valby, Denmark) V.1- 1948- Volume(issue)/page/year: 43,539,1963

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 1500 ug/kg

SEX/DURATION :: female 2 day(s) pre-mating female 1 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)

REFERENCE :: AJOGAH American Journal of Obstetrics and Gynecology. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1920- Volume(issue)/page/year: 117,167,1973

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 40 mg/kg

SEX/DURATION :: female 10 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)

REFERENCE :: FESTAS Fertility and Sterility. (American Fertility Soc., 608 13th Ave. S, Birmingham, AL 35282) V.1- 1950- Volume(issue)/page/year: 23,196,1972

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 2400 ug/kg

SEX/DURATION :: female 3 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles)

REFERENCE :: JRPFA4 Journal of Reproduction and Fertility. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1960- Volume(issue)/page/year: 37,269,1974 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X9388 No. of Facilities: 27 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 191 (estimated) No. of Female Employees: 82 (estimated)

点击显示

地屈孕酮安全信息

[ 安全声明 (欧洲) ]:
S26-S37/39

[ 危险品运输编码 ]:
3276

[ WGK德国 ]:
3

[ 包装等级 ]:
III

[ 危险类别 ]:
6.1

地屈孕酮合成路线

详细合成路线

地屈孕酮上下游产品

地屈孕酮上游产品

地屈孕酮下游产品

地屈孕酮文献

Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.

Gynecol. Endocrinol. 29(2) , 165-8, (2013)

It is established that hormone therapy (HT) is related with significant increased prothrombotic risk factor. The aim of our study was to assess the effects of oral hormone therapy (o-HT) and transderm...

Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety.

Maturitas 76(1) , 10-21, (2013)

HRT is known to be effective for the relief of menopausal symptoms and prevention of osteoporosis. HRT should be tailored to the woman, enhancing the beneficial effects of the treatment while minimizi...

Hormone replacement therapy regimens in chemotherapy-induced premature ovarian failure and the subsequent correction of hormone levels.

Neuro Endocrinol. Lett. 33(7) , 697-702, (2012)

Premature ovarian failure (POF) is a consequence of gonadotoxic chemoradiotherapy given in antyneoplasia treatment. In young women it will correlate with menopausal symptoms which tend to appear due t...

更多文献